Abstract
The popularity of monoamine oxidase type B inhibitors (MAOIBs) in early Parkinson’s disease decreased after their use was found to be associated with increased mortality. But a recent meta-analysis of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
